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Abstract: Assays to simultaneously detect multiple potential agents of bioterrorism are 
limited. Two multiplex PCR and RT-PCR enzyme hybridization assays (mPCR-EHA, 
mRT-PCR-EHA) were developed to simultaneously detect many of the CDC category “A” 
bioterrorism agents. The “Bio T” DNA assay was developed to detect: Variola major 
(VM),  Bacillus anthracis (BA),  Yersinia pestis (YP),  Francisella tularensis (FT) and 
Varicella zoster virus (VZV). The “Bio T” RNA assay (mRT-PCR-EHA) was developed to 
detect: Ebola virus (Ebola), Lassa fever virus (Lassa), Rift Valley fever (RVF), Hantavirus 
Sin Nombre species (HSN) and dengue virus (serotypes 1-4). Sensitivity and specificity of 
the 2 assays were tested by using genomic DNA, recombinant plasmid positive controls, 
RNA transcripts controls, surrogate (spiked) clinical samples and common respiratory 
pathogens. The analytical sensitivity (limit of detection (LOD)) of the DNA asssay for 
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genomic DNA was 1×10
0~1×10
2 copies/mL for BA, FT and YP. The LOD for VZV whole 
organism was 1×10
-2 TCID50/mL. The LOD for recombinant controls ranged from 
1×10
2~1×10
3copies/mL for BA, FT, YP and VM. The RNA assay demonstrated LOD for 
RNA transcript controls of 1×10
4~1×10
6 copies/mL without extraction and   
1×10
5~1×10
6 copies/mL with extraction for Ebola, RVF, Lassa and HSN. The LOD for 
dengue whole organisms was ~1×10
-4 dilution for dengue 1 and 2, 1×10
4 LD50/mL and 
1×10
2 LD50/mL for dengue 3 and 4. The LOD without extraction for recombinant plasmid 
DNA controls was ~1×10
3 copies/mL (1.5 input copies/reaction) for Ebola, RVF, Lassa 
and HSN. No cross-reactivity of primers and probes used in both assays was detected with 
common respiratory pathogens or between targeted analytes. Clinical sensitivity was 
estimated using 264 surrogate clinical samples tested with the BioT DNA assay and 549 
samples tested with the BioT RNA assay. The clinical specificity is 99.6% and 99.8% for 
BioT DNA assay and BioT RNA assay, respectively. The surrogate sensitivities of these 
two assays were 100% (95%CI 83-100) for FT, BA (pX02), YP, VM, VZV, dengue 2,3,4 
and 95% (95%CI 75-100) for BA (pX01) and dengue 1 using spiked clinical specimens. 
The specificity of both BioT multiplex assays on spiked specimens was 100% (95% CI 99-
100). Compared to other available assays (culture, serology, PCR, etc.) both the BioT 
DNA mPCR-EHA and BioT RNA mRT-PCR-EHA are rapid, sensitive and specific assays 
for detecting many category “A” Bioterrorism agents using a standard thermocycler. 
Keywords:  Multiplex PCR; simultaneous detection; Variola major; Bacillus anthracis; 
Yersinia pestis; Francisella tularensis; Ebola virus; Lassa fever virus; Rift Valley Fever 
virus; Hantavirus; dengue virus 
 
1. Introduction 
Biological weapons pose a significant threat. Many virulent and pathogenic organisms can be used 
individually or together as weapons. This use could cause not only high rates of morbidity and 
mortality among the population but also significant societal disruption and cost [1,2]. The Centers for 
Disease Control and Prevention classified these biological agents as category “A”, “B” or “C” agents 
based on the potential of threat. The category “A” bioterrorism agents include Variola major (VM, 
smallpox),  Bacillus anthracis (BA, anthrax), Yersinia pestis (YP, plague), Clostridium botulinum 
(botulism), Francisella tularensis (FT, tularemia) and a group of RNA viruses that cause hemorrhagic 
fevers (VHFs) [3-8]: Lassa fever virus and New World arenaviruses (Arenaviridae), Rift Valley fever 
(RVF) and hantavirus (Bunyaviridae), Ebola virus and Marburg viruses (Filoviridae) and dengue 
virus, Omsk hemorrhagic fever virus and Kyanasur Forest disease virus (Flaviviridae).  
In a suspected bioterrorist attack, rapid diagnosis is critical for effective public health responses. 
The treatment for the various DNA organisms is very specific and would be possible only if the 
causative organisms were promptly identified. All of the described RNA viruses except for dengue are 
highly infectious by aerosol transmission and no specific treatment has been demonstrated as safe and 
effective for the hemorrhagic fevers [7]. The rapid screening of suspected samples would help control Viruses 2009, 1                              
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the spread and ensure accurate treatment of the diseases. Current available diagnostic tests for CDC 
category “A” bioterrorism agents (e.g., cell culture, serology) are time consuming, have less than 
optimal sensitivity and specificity or cannot test for multiple agents simultaneously [9-12]. Newer 
molecular methods are either singleplex real-time PCR assays that are not available outside the CDCs 
LRN network or small commercial multiplex PCR assays that are linked to expensive machines (and 
also not easily available) [13,14]. There is a need for precise, rapid, simple and robust diagnostic 
assays to detect a large number of these agents for both clinical treatment and to prevent panic among 
the public and authorities.  
Large multiplex PCR assays have the advantage of detecting many pathogens from the same 
clinical sample in only a few hours while being highly sensitive and specific [15-19]. In this present 
study, two large multiplex-PCR assays were developed for simultaneous detection of many of the CDC 
category “A” DNA and RNA based bioterrorism agents. The BioT DNA multiplex  PCR-enzyme 
hybridization assay (BioT DNA mPCR-EHA) was developed for simultaneous detection of: VM, BA, 
YP, and FT. The BioT RNA multiplex reverse transcription PCR-EHA (BioT RNA mRT-PCR-EHA) 
was developed for simultaneous detection of Ebola virus, Lassa virus, RVF virus, Hanta virus Sin 
Nombre species(HSN), and dengue virus (serotypes 1-4). Varicella-Zoster virus while not a category 
“A” agent was chosen as a target for the BioT DNA assay in order to positively identify the cause of 
rash or lesions in suspected smallpox patients.  
2. Results  
2.1. Analytical Sensitivity  
Each assay’s analytical sensitivity was determined by testing duplicate DNA samples, RNA 
transcripts or whole organism for different analytes and repeated at least three times to determine the 
assay’s reproducibility. This LOD was determined by the lowest dilution which gave a positive EHA 
reading greater than 0.4. The LOD of the DNA assay for genomic DNA and whole organisms is shown 
in Table 1.  
Table 1. Limits of detection for BioT DNA assay using genomic DNA and plasmid 
controls for each organism. 
Organism  Genomic DNA LOD  Plasmid Control LOD 
BA pX01  1 × 10
1 copies/mL 1 × 10
2 copies/mL
BA pX02  1 × 10
2 copies/mL 1 × 10
2 copies/mL
FT  1 × 10
1 copies/mL 1 × 10
3 copies/mL
YP  1 × 10
0 copies/mL 2.5 × 10
2 copies/mL
VZV  1 × 10
-2 TCID50/mL ND 
VM  ND  5 × 10
2 copies/mL
ND - The LOD of genomic DNA for Variola major wasn’t tested because the genomic DNA of VM was not available 
and no control for VZV was tested since whole virus is readily available.  
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The LOD for genomic DNA was at 1×10
1 copies/mL for BA pX01 and FT, 1×10
2 copies/mL for BA 
pX02 and 1×10
0 copies/mL for YP. The LOD for VZV whole organism was 1×10
-2 TCID50/mL. The 
LOD for recombinant plasmid DNA controls was evaluated in the same way and is shown in Table 1. 
The LOD for both BA pX01 and BA pX02 recombinant controls was 1×10
2 copies/mL. The analytical 
sensitivity for FT, YP and VM were 1×10
3, 2.5×10
2 and 5×10
2 copies/mL, respectively.  
The LOD of the RNA assay with or without extraction for RNA transcript control is shown in  
Table 2.  
Table 2. The limits of detection of the BioT RNA assay for RNA transcript control, 
plasmid controls, or whole virus. 
 
Organism 
Without Extraction  With Extraction 
RNA Controls  Plasmid Controls RNA Controls/Whole Virus 
Copies/mL Copies/rxn  Copies/mL Copies/rxn Concentration  Copies/rxn
Ebola  1 × 10
6  1500  1 × 10
3 1.5 1 × 10
5 copies/mL  1200
RVF  1 × 10
6  1500  1 × 10
3 1.5 1 × 10
6 copies/mL  12000
Lassa  1 × 10
5  150  1 × 10
3 1.5 1 × 10
5 copies/mL  1200
Hanta SN  1 × 10
4  15  1 × 10
3 1.5 1 × 10
5 copies/mL  1200
Dengue 1        1 × 10
-4 dilution   
Dengue 2        1 × 10
-3~-4 dilution   
Dengue 3        1 × 10
4-5 LD50/mL   
Dengue 4        1 × 10
2 LD50/mL   
 
The LOD without extraction for RNA transcript control was at 1×10
6 copies/mL for Ebola and 
RVF, 1×10
5 copies/mL for Lassa and 1×10
4 copies/mL for HSN. The LOD with extraction for RNA 
transcript control was at 1×10
5 copies/mL for Ebola, Lassa and HSN, and 1×10
6 copies/mL for RVF.  
The LOD for dengue whole organism (4 serotypes) is shown in Table 2. The LOD for dengue 
whole organisms was approximately 1×10
-4 dilution for dengue 1 and 2, 1×10
4 LD50/mL for dengue 3 
and 1×10
2 LD50/mL for dengue 4.  
The LOD without extraction for recombinant plasmid DNA controls was evaluated in the same way 
and is shown in Table 2. The LOD without extraction for recombinant plasmid DNA controls was at 
1×10
3  copies/mL for all 4 targets. This demonstrated outstanding sensitivity (~1.5 input 
copies/reaction) for the primers and probes of the RNA assay in PCR-EHA and suggests that our RNA 
controls did not represent the LOD we would expect to see in true clinical testing. We hypothesize that 
our RNA transcripts are unstable and degradation is likely during the dilution and extraction process.  
2.2. Analytical Specificity  
The analytical specificity of the assays was determined using a number of closely related organisms 
and other common respiratory pathogens that might be found in clinical samples. These samples were 
tested for cross-reactivity to the primers and probes. Table 3 described the organisms, the dilutions 
used and the results.  Viruses 2009, 1                              
 
 
445
Table 3. Specificity of the BioT DNA and BioT RNA assays was tested against different 
pathogens. 
A. The organism, dilution and the result of the specificity testing for BioT DNA multiplex 
assay. 
Organisms 
Concentration of 
strains 
Target 
B. anthracis  F. tularenisis  V. major   Y. pestis VZV 
Adenovirus C  10
3 TCID50/mL Neg  Neg  Neg  Neg  Neg 
Influenza A  10
3 TCID50 /mL  Neg  Neg  Neg  Neg  Neg 
Francisella philomiragia  10
-4dilution Neg  Neg  Neg  Neg  Neg 
Bacillus cereus  10
-4dilution Neg  Neg  Neg  Neg  Neg 
Bacillus thuringiensis  10
-4dilution Neg  Neg  Neg  Neg  Neg 
Yersinia pseudotuberculosis  10
-4dilution Neg  Neg  Neg  Neg  Neg 
Yersinia enterocolitica  10
-4dilution Neg  Neg  Neg  Neg  Neg 
Clostridium perfringens   Neg  Neg  Neg  Neg  Neg 
Vaccinia Virus    Neg Neg  Neg  Neg  Neg 
Epstein-Barr virus  10
2 TCID50/mL Neg  Neg  Neg  Neg  Neg 
Cytomegalovirus 10
4 TCID50 /mL  Neg  Neg  Neg  Neg  Neg 
Mycoplasma pneumoniae   10
-3dilution Neg  Neg  Neg  Neg  Neg 
Chlamydia pneumoniae   Neg  Neg  Neg  Neg  Neg 
Legionella pneumophila   Neg  Neg  Neg  Neg  Neg 
Mycoplasma pneumoniae   10
-3dilution Neg  Neg  Neg  Neg  Neg 
Human metapneumovirus  10
4 TCID50/mL Neg  Neg  Neg  Neg  Neg 
Respiratory syncytial virus A  10
3 TCID50/mL Neg  Neg  Neg  Neg  Neg 
Bacillus anthracis  10
-4dilution >3.0  Neg  Neg  Neg  Neg 
Francisella tularensis  10
4 CFU/mL Neg >3.0  Neg  Neg  Neg 
Variola major  10
-4dilution Neg  Neg  >3.0  Neg  Neg 
Yersinia pestis  10
-4dilution Neg  Neg  Neg  >3.0  Neg 
Varicella-Zoster virus  10
3 TCID50/mL Neg  Neg  Neg  Neg  >3.0 
Negative control    Neg  Neg  Neg  Neg  Neg 
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B. The organism, dilution and the result of the specificity testing for BioT RNA multiplex 
assay. 
Organisms 
Concentration of 
strains 
Target 
Ebola   Hanta  Lassa  RVF   Dengue  IC  
Human parainfluenza viruses 1  10
3TCID50  /mL  Neg Neg Neg  Neg Neg Neg 
Human parainfluenza viruses 2  10
3TCID50 /mL  Neg  Neg  Neg  Neg  Neg  0.957 
Human parainfluenza viruses 3  10
3TCID50  /mL  Neg Neg Neg  Neg Neg Neg 
Influenza A  10
3TCID50  /mL  Neg Neg Neg  Neg Neg Neg 
Mycoplasma pneumoniae   10
4 cells /mL  Neg  Neg  Neg  Neg  Neg  Neg 
Respiratory syncytial virus A  10
3TCID50  /mL  Neg Neg Neg  Neg Neg Neg 
Respiratory syncytial virus B  10
3TCID50  /mL  Neg Neg Neg  Neg Neg Neg 
Varicella-Zoster virus  10
3TCID50  /mL  Neg Neg Neg  Neg Neg Neg 
Human Coronavirus OC43  10
3TCID50  /mL  Neg Neg Neg  Neg Neg Neg 
Enterovirus type 71  10
3TCID50  /mL  Neg Neg Neg  Neg Neg Neg 
Human Coronavirus 229E  10
3TCID50  /mL  Neg Neg Neg  Neg Neg Neg 
Adenovirus type 3  10
3TCID50  /mL  Neg Neg Neg  Neg Neg Neg 
Staph pneumoniae  10
4 cfu /mL  Neg  Neg  Neg  Neg  Neg  Neg 
Staph aureus  10
3 cfu /mL  Neg  Neg  Neg  Neg  Neg  Neg 
Legionella micdadei 10
4 cells /mL  Neg  Neg  Neg  Neg  Neg  Neg 
Ebola 10
4  copies/ml  1.786  Neg Neg  Neg Neg Neg 
Hanta 10
4  copies/ml  Neg  3.796  Neg  Neg Neg Neg 
Lassa 10
4  copies/ml  Neg Neg  2.651  Neg Neg Neg 
RVF 10
4 copies/ml  Neg  Neg  Neg  3.259  Neg  Neg 
Dengue 1  10
-2 dilution  Neg  Neg  Neg  Neg  2.282  Neg 
Dengue 2  10
-2 dilution  Neg  Neg  Neg  Neg  3.943  Neg 
Dengue 3  5x10
5 TCID50/ml Neg  Neg  Neg  Neg  4.000  Neg 
Dengue 4  10
4TCID50 /mL  Neg  Neg  Neg  Neg  3.249  Neg 
Negative control    Neg  Neg Neg  Neg Neg Neg 
Detection  control    3.502 3.980 2.454  3.903 3.876 4.000 
Neg = negative. Optical density readings less than 0.400 are indicated by negative.  
The positive OD reading is the average OD reading of duplicate samples. 
 
No cross-reactivity between primers, probes and these organisms was detected in either assay. The 
internal control probe in the RNA assay can identify human parainfluenza virus 2 (HPIV-2) because 
the RNA assay used HPIV-2 as an internal control. HPIV-2 produced negative result for all other 
primers and probes in this assay except the internal control which should be positive.  
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2.3. Evaluation of the Clinical Specimens 
Two hundred and sixty four clinical samples (196 NP swabs, 45 skin swabs, 15 serum, 7 sputum,  
1 tracheal) were tested with the DNA assay. The results were shown in Table 4A. In this testing there 
were three indeterminants for FT and when reprobed as per standard protocol for indeterminants (OD 
of 0.300-0.399) they were found to be negative. There was one false positive (low positive) for FT 
(OD=0.838) which when retested was also found to be negative. The clinical specificity of the BioT 
DNA assay was 99.6% (263/264) (95% CI 98-100). Of the 549 clinical samples that were tested by the 
RNA assay, there was one false positive (OD=0.626) for HSN and when retested as per standard 
protocol for false positive (OD>0.400) it was found to be negative (OD=0.040). The overall clinical 
specificity of the BioT RNA assay was 99.8% (548/549) (95% CI 99-100).  
2.4. Surrogate clinical testing 
The results were shown in Table 4A. Surrogate clinical NP samples with FT (20/20), BA pX02 
(20/20), YP (20/20), and skin specimens with VZV (20/20) and VM (20/20) were detected and had 
sensitivities of 100% (95% CI 83-100). BA pX01 was detected in 19/20 NP samples (sensitivity 95% 
(95% CI 75-100).  
There was one sample positive for VZV in a clinical specimen spiked with VM. Using the standard 
assay protocol to re-probe any positive (~30 minute procedure) it was found to be a true negative. This 
was most likely a technical error. However, even counting it as a false positive would not have much 
of an impact on the specificity for VZV which was 99.8% (95%CI 99-100). One sample tested very 
low positive for VM (OD=0.434) in the BA pX01 spiked samples. Re-probing of the PCR product 
continued to show the sample to be positive. However, retesting the original clinical sample 
demonstrated it to be negative. Therefore, this represented a true false positive (1/400 samples). 
Specificity for VM was 99.8% (95% CI 99-100). No other false positives where detected using the FT, 
BA pX01, BA pX02, and YP probes (specificities 100% (95% CI 99-100). Finally, all 36 negative 
control M4 samples were negative for all organisms.  
A total of 104 serum specimens were used to test the surrogate clinical sensitivity and specificity of 
the RNA assay. The results are shown in Table 4B. For dengue 2, 3, and 4, 20/20 serum samples 
spiked were correctly detected resulting in sensitivities of 100% (95%CI 83-100), and dengue 1 testing 
showed 19/20 samples were correctly detected and the sensitivity was 95% (95% CI 75-100). No false 
positive results were found using any of the probes (including Ebola, HSN, RVF, and Lassa) and the 
BioT RNA assay showed 100% specificity (95% CI 96-100). The 24 negative control samples were 
negative for all targets making the overall specificity of the assay 100% (95% CI 99-100).  
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Table 4. The sensitivity and specificity of BioT DNA and BioT RNA assays in spiked 
clinical specimens. 
A. Sensitivity and specificity of BioT DNA assay. 
                    Organism 
 
Detail 
Francisella 
tularensis 
Bacillus 
anthracis (pX01) 
Bacillus 
anthracis (pX02) 
Yersinia pestis  VZV  Variola major 
Spiking Concentration 
1×10
4 
copies/ml 
1×10
4 
copies/ml 
1×10
5 
copies/ml 
1×10
5 
copies/ml 
1×10
0 
TCID50/ml 
1×10
4 
copies/ml 
OD(mean±SD) 2.643±0.843  2.727±1.294  3.289±0.289 2.638±0.458 3.968±0.074 3.564±0.464 
Sensitivity  
(95%CI) 
100%(20/20) 
(83-100%) 
95%(19/20) 
(75-100%) 
100%(20/20) 100%(20/20) 100%(20/20) 100%(20/20) 
Negative  Controls  (-)  (-) (-) (-) (-) (-) 
M4  NEG  controls  6/6  6/6 6/6 6/6 6/6 6/6 
False Positive   
0.434 VM  
(re-amp -) 
   
0.733 VZV  
(re-probe -) 
This experiment 
Specificity, clinical 
(95%CI) 
100%(100/100) 
(96-100%) 
100%(100/100) 100%(100/100) 100%(100/100) 
99%(99/100) 
(95-100%) 
99%(99/100) 
Specificity-Controls 
(95%CI) 
100%(36/36) 
(90-100%) 
100%(36/36) 100%(36/36) 100%(36/36) 100%(36/36) 100%(36/36) 
Specificity, overall 
(95%CI) 
100% (400/400) 
(99-100%) 
100%(400/400) 100%(400/400) 100%(400/400) 
99.8%(399/400) 
(99-100%) 
99.8%(399/400) 
 
B. Sensitivity and specificity of surrogate testing for BioT RNA assay. 
             Organism 
 
Detail 
Dengue 1  Dengue 2  Dengue 3  Dengue 4 
Spiking 
Concentration 
1×10
-2 
dilution 
1×10
-2 
dilution 
5×10
5 
LD50/mL 
1×10
4 
LD50/mL 
OD(mean±SD) 2.486±1.305  1.077±0.373  1.248±0.147  1.462±0.517 
Sensitivity  
(95%CI) 
95%(19/20) 
(76.2-98.8%) 
95%(20/20) 
(83.9-99.9%) 
100%(20/20) 
(83.9-99.9%) 
100%(20/20) 
(83.9-99.9%) 
Negative Controls  (-)  (-)  (-)  (-) 
NEG sample   6/6  6/6  6/6  6/6 
This experiment 
Specificity 
(95%CI) 
For Ebola 
100% 
(104/104) 
(96-100%) 
For Lassa 
100% 
(104/104)  
(96-100%) 
For RVF  
100% 
(104/104) 
(96-100%) 
For HSN 
100% 
(104/104) 
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3. Discussion 
The current study describes the development of two multiplex assays for detecting many CDC 
category “A” bioterrorism agents simultaneously. The first multiplex  assay detects: B. anthracis,   
F. tularensis, Y. pestis, V.major, and Varicella zoster virus while the second multiplex assay detects: 
Ebola virus (Zaire), Lassa fever virus, Rift Valley fever virus, Hantavirus (Sin Nombre), and dengue 
virus (serotypes 1-4). Varicella-Zoster virus while not a category “A” agent was chosen as a target for 
the BioT DNA assay in order to positively identify a possible cause of rash or lesions in suspected 
smallpox patients in addition to demonstrating that a clinical sample was VM negative. It is presumed 
that virtually all of the patients coming in to a hospital emergency room with a concern for VM will 
not actually have this virus (short of a bioterrorism attack).  
The virulence of B. anthracis has been associated with two mega plasmids,
 pX01 and pX02 [20]. 
Plasmid pX02 (60 MDa) carries the genes
 required for synthesis of an antiphagocytic poly-D-glutamic
 
acid capsule facilitating host immune system evasion [20-25]. The 110-MDa plasmid pX01 is required 
for synthesis
 of the three anthrax toxin proteins, edema factor (EF), lethal
 factor (LF), and protective 
antigen (PA). These proteins
 act in binary combinations to produce the two anthrax toxins:
 edema 
toxin (PA and EF) and lethal toxin (PA and LF) [26]. Isolates lacking either the pX01 or pX02 plasmid 
are
 considered either avirulent or significantly attenuated [27,28]. In the present study, 2 sets of 
primers and probes were designed from the conserved regions of the PA  and  Cap  gene located 
respectively on the plasmids pX01 and pX02 for B. anthracis. Only clinical samples that give positive 
signals for both primers and probe sets will be considered “positive” for BA. Since we demonstrated 
high sensitivity and specificity for both the pX01 and the pX02 primer and probe sets, our assay 
should work well for detecting both targets in BA.  
The analytical testing of both multiplex assays demonstrated excellent LOD (1-10 input copies for 
all analytes) and no significant cross reactivity with a large number of agents that might be in clinical 
samples. 
The clinical sample types used in the BioT DNA assay spiking experiments meet the CDC 
requirements for appropriate diagnostic samples for each Category “A” agent. CDC requires collection 
of blood, skin lesions or respiratory secretions for diagnosis of B. anthracis. Respiratory secretions and 
blood should be collected for diagnosis of F. tularensis, especially inhalational tularemia. Blood and 
lymphoid tissue specimens should be collected for diagnosis of Y. pestis. Bronchial/tracheal washing 
should be taken from suspected pneumonic plague patients. The skin of the vesicle top should be taken 
for diagnosis of VM. CDC prefers to collect blood or biopsy material of the lung and bone marrow 
aspirate for PCR diagnosis of VHF. After considering the CDC requirements, NP swab specimens 
were chosen for creating the surrogate “positive” clinical samples used in the spiking experiments for  
B. anthracis, Y. pestis, and F. tularensis, skin swab specimens were chosen for V. major and Varicella 
zoster virus, and serum specimens were chosen for the spiking experiments for dengue virus.  
In the evaluation of the clinical specimens, 813 specimens in total were tested demonstrating very 
high sensitivity (in spiked samples) and specificity (spiked and unspiked samples) confirming that the 
assays are applicable to testing different clinical samples without inhibition or cross-reactivity and 
demonstrating their potential utility in clinical or public health use.  Viruses 2009, 1                              
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 There are many molecular diagnostic methods that have been developed to detect bioterrorism 
agents [13,14,29]. Real-time PCR and micro-array are currently two of the most commonly reported 
molecular diagnostic methods. MGB probe-based real-time PCR assays were developed for detecting  
Y. pestis, F. tularensis and B. anthracis simultaneously [29]. For this test the sample must be tested 
simultaneously with a seperate singleplex assay for each of these three targets. Two commercial triplex 
(multiplex) real time PCR kits and machines were developed by Cepheid [13] and Idaho Technology, 
Inc. [14] to detect B. anthracis, Y. pestis and F tularensis, however, their assays can only be used on 
their machines. Therefore, laboratories with standard thermocyclers or real-time machines cannot run 
these assays. We were unable to purchase reagents for comparison testing. For viral hemorrhagic fever 
agents, several TaqMan or SYBR green real-time one-step RT-PCR assays have been developed for 
detecting and serotyping dengue [30-32]. A single-tube multiplex PCR was developed to identify the 
serotype of dengue virus which had been previously screened by real-time PCR [33]. The detection for 
Ebola virus, RVF and Lassa is still dependent on serology testing in most laboratories but additional 
RT-PCR methods have been recently developed. A German group established 6 one-step, real-time 
RT-PCR assays for Ebola virus, Marburg virus, Lassa virus, Crimean-Congo hemorrhagic fever virus, 
Rift Valley fever virus (RVFV), dengue virus (DENV), and yellow fever virus (YFV) [34]. These 
assays cannot distinguish all the targets simultaneously.  
The BioT multiplex DNA and RNA assays are two new methods to compliment existing testing 
strategies. Possible advantages over published methods include increased number of analytes per test  
(5 vs. 1 or 3), stability of reagents, use of common technology and cost. Real-time reagents have 
shorter shelf lives than our HRP labeled reagents because of their use of fluorescent probes. In addition, 
our assay utilizes a standard PCR thermocycler and ELISA plate reader which cost tens of thousands 
of dollars less than real-time PCR machines and the reagent costs for our multiplex PCR-EHA format 
are less than real-time reagents. Additional side by side comparative research should be performed to 
assess the multiplex BioT DNA and RNA assays against other existing methods. 
Both the BioT DNA assay and BioT RNA assay were developed using manual nucleic acid 
extraction (Roche). This method requires skilled technicians and is labor intensive. Recently there has 
been increased use of automated sample preparation using systems such as Roche’s MagnaPure 
Compact [35,36], the Qiagen BioRobot M48 [37,38] and Biomerieux’s NucliSens Extractor [39]. 
These robotic systems can dramatically increase throughput and decrease hands-on time. We recently 
demonstrated dramatic decreases in technician time (by half) using automated extraction and both 
EHA detection and automated microarray detection [40]. However, automation can have hidden 
variables that effect costs, sensitivity and reproducibility. The chemistry of each assay, including 
buffers and enzymes used, and especially the target (RNA vs. DNA and size) and clinical matrix can 
affect the results you obtain with some of the automated systems. We demonstrated with the BioT 
DNA assay that the sensitivity using Roche’s High Pure Viral Nucleic Acid Kit for extraction was one 
log better than using the Roche MagNAPure Compact system which also had less consistent 
reproducibility (data not shown). Ultimately, the goal of our laboratory is to develop fully contained, 
automated, hands-off devices that can extract nucleic acid, amplify a target, and detect it while being 
fast, accurate and inexpensive. This technology must be robust and flexible to different targets and 
matrix material (transport medium and clinical material). Medium to large multiplex assays as 
described in this paper are steps in this direction.  Viruses 2009, 1                              
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4. Materials and methodology 
4.1. Primers and Probe Design 
The primers and probes used in these 2 assays were designed from highly conserved regions of 
specific genes for each organism listed in Table 5A and 5B.  
Table 5A. Primer and probe sequence using in the BioT DNA multiplex PCR-EHA assay. 
Organisms 
Primers &  
probes 
Gene 
Size of 
Amplicon 
Sequences 
Bacillus 
anthracis 
BA pX01-1F 
PA 
(pX01) 
311 bp 
5'-ggatttcaagttgtactggaccgat-3' 
BA pX01-1R  5'-ctgtacggatcagaagccgtgctcca-3' 
BA pX01-P  5'-ctagtgataacttacaattgccagaat-3'’ 
BA pX02-1F 
Cap 
(pX02) 
305 bp 
5'-tgtccattatatggaatggtagcagtg-3' 
BA pX02-1R  5'-tggtacatctgcgcgaatgatatattggt-3' 
BA pX02-P  5’-acattcacaaataagtgcttctgcttc-3' 
Francisella 
tularensis 
FT-1F  
Tul 4  156 bp 
5'-ataacccaccaaggaagtgtaagat-3' 
FT-1R 5'-cacttaccgctacagaagttatta-3' 
FT-P 5'-aggctccagaaggttctaagtgccatgata-3’ 
Yersinia 
pestis 
YP-1F  
VA 195  bp 
5'-cggaggtttttgccaataga-3' 
YP-1R 5’-actgccatgaacgcccgcaattc-3' 
YP-P 5'-tgccattcttaaaggcggtcatta-3' 
Variola 
major 
VM-1F 
HA 124  bp 
5'-cacaacagacaagacgtccg-3' 
VM-1R 5'-catcattggcggttgattta-3' 
VM-P 5'-acgtcgggaccaattactaataaaga-3' 
Varicella 
Zoster virus 
VZV-1F 
ORF29 226  bp 
5'-gctgacacagccttgcacgcagaag-3' 
VZV-1R 5'-tcggtcatcccgctatcctccacctcag-3' 
VZV-P 5'-caacactggaatttacgaagaaactccaacagatatc-3' 
 
Table 5B. Primer and probe sequence using in the BioT RNA multiplex RT-PCR-EHA assay. 
Organisms 
Primers & 
 probes* 
Gene 
Size of 
Amplicon 
Sequences 
Ebola virus  
(Zaire) 
Ebola-1F  
L 243  bp 
5'gatgcagtattcgagcctaatgttctag-3' 
Ebola-1R 5'-gtgtttgaacattgcgagtcggataag-3' 
Ebola-P 5'-actcgagtatctactaccacaatatcggaac-3' 
Lassa fever 
virus 
Lassa-1F  
L 197  bp 
5'-agcctgatcccagatgccacacatctag-3' 
Lassa-1R   5'-tgctgttggagcggctgatggtctcag-3' 
Lassa-P 5'-gcctggttgagtgcaacaaccactatctgtgtctcaactg-3' 
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Table 5B. Cont. 
Organisms 
Primers & 
 probes* 
Gene 
Size of 
Amplicon 
Sequences 
Rift Valley 
fever virus 
RVF-1F  
GP2 196  bp 
5'-gacgcagcattttgctctgcttatg-3' 
RVF-1R   5'- gttgtgcaaggctcaactctctggatg-3' 
RVF-P 5'-ctttatgtgtagggtatgagagagtggttgtga-3' 
Hantavirus 
(Sin nombre) 
Hanta-1F  
S 
segment 
222 bp 
5'-gcaccctcaaagaagtgcaagacaaca-3' 
Hanta-1R   5'-gaagccaatttctgagctgcaata-3' 
Hanta-P 5'-gctgtgtctgcattggaiaccaaactcg-3'' 
Dengue virus 
Dengue-2F  
3’UTR 
141 bp 
225 bp 
5'-aaggactagiggttakaggagacc-3' 
Dengue-2R A 
Dengur-2R B  
5'-ctgttgattcaacagcaccattc-3'  
5'-ctgttggatcaacaacaccaatc-3' 
Dengue-P 5'-aacagcatattgacgctgggaiagaccaga-3' 
* F is forward primer, R is reverse primer. 
 
The primers and probe for the DNA assay specifically targeted the Tul4 gene for F. tularensis, the 
HA gene for V. major, the ORF29 gene for the Varicella zoster virus and the Virulence Antigen gene 
for Y. pestis. 2 pairs of primers for B. anthracis were designed from the conserved regions of the 
Protective Antigen (PA) and Cap gene located respectively on the plasmids pX01 and pX02 because 
both plasmids are required for pathogenicity. The primers and probes for the RNA assay specifically 
targeted the L gene for Ebola, the GP2 gene for RVF, the L gene for the Lassa, the S segment for 
Hanta and the 3’UTR for dengue. 
4.2. Bacterial Species and Genomic DNA 
Varicella zoster virus (VZV) and all four serotypes of dengue virus were obtained from ATCC. 
Genomic DNA of FT and of BA (BA pX01-Sterne strain) were obtained from the Medical College of 
Wisconsin. Genomic DNA of YP was obtained from the Blood Center of Wisconsin. The genomic 
DNA of BA (BA pX02) was obtained from the University of Chicago.  
4.3. Generation of Recombinant Positive Controls 
To create positive controls, PCR products generated from whole organisms were purified and 
cloned into plasmids using the TOPO TA cloning system (Invitrogen, Carlsbad, CA), following the 
manufacturer’s instructions. All positive controls were sequenced to verify the amplicon sequences 
and the possibilities of any mismatches generated during cloning. The positive controls were further 
amplified to generate large quantities that were purified using Qiagen Plasmid Midi Kit (Qiagen, 
Valencia, CA). The synthetic RNA standards were generated from linearized target sequence plasmids 
by using T7 in vitro transcription system (Promega, Madison, WI).  
The quantity of DNA and RNA transcripts were measured by the absorbance at 260 nm and the 
purity of the DNA or RNA by the ratio at A260/280. To determine the approximate copy number of 
plasmid controls and synthetic RNA controls, the absorbance value of the positive control (A260) was Viruses 2009, 1                              
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used in combination with Avogadro’s Number (6.022 × 10
23) as described by Khanna et al. (2005) 
[41]. The RNA transcripts were diluted in RNase and DNase free water with RNase Inhibitor (Applied 
Biosystems, Foster City, CA), frozen at -80˚C in 30 μL aliquots. Serial dilutions of the plasmids and 
RNA transcripts were used to establish the analytical sensitivity and specificity of BioT DNA and 
RNA multiplex assays.  
4.4. The Standard Protocol of the BioT DNA and RNA Multiplex Assays  
4.4.1. PCR protocol for BioT DNA mPCR-EHA assay 
Ten μL of extracted DNA were amplified in a 50 μL PCR reaction that contained 2.25 mM MgCl2 
(Applied Biosystems), 0.8mM dNTP (Applied Biosystems), 1× PCR Buffer II (Applied Biosystems), 
2.5 U of AmpliTaq Gold DNA polymerase (Applied Biosystems) and 6 pairs of primers at a final 
concentration 250nM for each forward primer and 500nM for each reverse primer. Amplification was 
performed in a GeneAmp 9700 thermocycler (Applied Biosystems). The PCR was carried out under 
the following conditions: 95º C for 10 min; 2 cycles of 95º C for 60 s, 55º C for 30 s and 72º C for  
45 s; 38 cycles of 94º C for 60 s, 60º C for 30 s and 72º C for 30 s; and then an extension step at 72º C 
for 7 min. 
4.4.2. RT-PCR protocol of BioT RNA mRT-PCR-EHA assay 
For the BioT RNA assay, a two-step RT-PCR was performed in a GeneAmp 9700 thermocycler 
(Applied Biosystems). cDNA was synthesized in a 20 uL reaction mixture containing 2.5 mM random 
hexamers (Applied Biosystems), 4 mM dNTPs (Applied Biosystems), 4mM MgCl2 (Applied 
Biosystems,), 1U/μL RNase inhibitor, 2.5U/μL MuLv reverse transcriptase (Applied Biosystems) and  
3 μl RNA. The reaction mixture was incubated for 5 min at 25℃ and for 30 min at 42℃ and then the 
transcriptase was inactivated at 95℃ for 5 min. 
Next, 10 μL of cDNA were amplified by adding 39.5 μL of a Multiplex Supermix that contained  
6 pairs of primers, appropriate buffers and 2.5 U of AmpliTaq Gold DNA polymerase (Applied 
Biosystems). The final concentration of primer is 250nM for each forward primer and 500nM for each 
reverse primer. Amplification was performed under the same conditions of the BioT DNA assay.  
PCR products from both DNA and RNA assays were purified using the QiaQuick PCR purification 
Kit (Qiagen). A total of 65 μL of 10 nM horseradish peroxidase labeled probe solution (Eurogentec, 
San Diego, CA) was added to wells of a 96 well NeutrAvidin-coated microtiter plate (Pierce, 
Rockford, IL) and hybridized with 5 μL of the purified PCR product at 42˚C for 30 minutes. The plate 
was washed 10 times with a 1X Wash Buffer. And then 200 μL of Tetramethyl benzidine substrate was 
added to each experimental well. The reaction was stopped by the addition of a stop solution (1N 
H2SO4) and the absorbance [optical density (OD)] was measured at 450 nm using a Molecular Devices 
spectrophotometer. The positive cut off value for this assay was chosen to be four times greater than 
the value of the negative control and greater than or equal to an OD value of 0.400 [15,16]. Viruses 2009, 1                              
 
 
454
4.5. Analytical Sensitivity 
The analytical sensitivity for the DNA assay was determined using serial dilutions of both DNA 
extracted from whole organisms and recombinant DNA controls. Ten-fold serial dilutions of genomic 
DNA (BA, YP, and FT), previously extracted from whole organisms and plasmid DNA controls were 
made (10
4 to 10
1 or 10
-1 copies/mL) in M4 medium (Remel, Lenexa, KS), extracted using the High 
Pure Viral Nucleic Acid Kit according to manufacturer’s instructions (Roche Applied Science, 
Indianapolis, IN) and then tested. VZV whole organism was serially diluted (10
3 to 10
-3 CFU/mL) in 
M4 and extracted using the same method.  
The analytical sensitivity for the RNA assay was determined using serial dilutions of both RNA 
transcripts and recombinant DNA controls for HSN, RVF, Lassa, and Ebola virus. The analytical 
sensitivity of the assay for dengue was determined using serial dilutions of all four serotypes of dengue 
virus. Ten-fold serial dilutions of RNA transcript and recombinant DNA control were made (10
7 to  
10
3 copies/mL for RNA transcripts, 10
6 to 10
2 copies/mL for recombinant DNA control) using two 
matrices: M4 medium and RNase/DNase-free water. The RNA and plasmid controls diluted in water 
were used as a template in RT-PCR to determine the limit of detection (LOD) without extraction. The 
RNA controls diluted in M4 were extracted to determine the LOD with extraction. Dengue   
(4 serotypes) whole virus was serially diluted at 10
-2 to 10
-5 dilutions for dengue serotypes 1 and 2 (the 
virus stock for these serotypes came from ATCC without quantitation ), 10
5 to 10
2 LD50/mL for dengue 
serotype 3, and 10
3 to 10
0 LD50/mL for dengue serotype 4. Diluted whole viruses were extracted using 
high pure viral nucleic acid kit (Roche) according to manufacturer’s instructions and tested. 
4.6. Analytical Specificity  
Specificity of the DNA and RNA assays were evaluated by respectively testing 17 and 15 common 
respiratory pathogens that could be present in clinical specimens for potential cross-reactivity. ATCC 
bacterial and viral strains tested by the DNA assay were diluted to 1×10
3 CFU/mL and   
1×10
2 -10
4 TCID50 /mL. ATCC bacterial or viral strains tested by the RNA assay were diluted to  
1×10
3 CFU/mL, 1×10
4 CFU/mL, 1×10
3 TCID50 /mL or 1×10
4 cells/mL respectively. The bacterial and 
viral strains were then tested using the same method as previously described. The plasmid DNA 
controls and whole virus, which are the targets of both BioT assays, were diluted and tested at 1 to 2 
log higher than the LOD using the same method. 
4.7. Evaluation of the Clinical Specimens 
For the DNA assay, 264 clinical samples (196 NP swabs, 45 skin swabs, 15 serum, 7 sputum,  
1 tracheal), were collected from 264 subjects at Children’s Hospital of Wisconsin and Froedtert 
Memorial Hospital during a 17-month period from October 2005 through March 2007 and were tested. 
Of the 264 subjects, 130 presented with respiratory symptoms and 134 presented without respiratory 
symptoms. Sixty three of the samples were children aged 0-6 years old, 20 were children aged 7-18 
years old, 154 were aged 19-65 years old, and 27 were older than 66. Of the 264 clinical samples 
tested, 139 were females and 125 were males.  Viruses 2009, 1                              
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For the RNA assay, 549 clinical samples (417 NP swabs, 95 skin swabs, 21 blood, 12 sputum,  
3 tracheal, 1 nasal swabs) were tested. The samples were collected from 418 subjects as described 
above. Of these samples, 302 were from the subjects with respiratory symptoms and 247 were from 
subjects that had no respiratory symptoms. Two hundred and thirty nine of the samples were from 
children age 0-6 years old, 106 were from children age 6-19 years old, 182 were from subjects age  
19-65 years old and 22 were from subjects older than 66. Of the 549 clinical samples tested, 258 were 
from females and 291 were from males. Any sample with OD value lower than 0.300 was considered 
negative. Any sample with OD value between 0.300-0.399 was considered indeterminant and was 
reprobed to confirm the results. Any sample with OD value over 0.400 was considered positive and 
was retested. 
4.8. Surrogate Positive Clinical Specimens  
To evaluate the performance of the DNA assay we used surrogate positive clinical samples. A total 
of 120 clinical NP swab and skin swab specimens that previously tested negative with the same assay 
were used for spiking experiments. Twenty clinical specimens were spiked with plasmid DNA positive 
control and six M4 transport medium specimens were set up as negative specimens for each of the six 
organisms mentioned (36 total). The recombinant positive controls of FT and BA pX01 were spiked 
into NP swab specimens at the concentration 1×10
4 copies/mL. The recombinant positive controls of 
YP and BA pX02 were spiked into NP swab specimens at the concentration 1×10
5 copies/mL. The 
recombinant positive control of VM was spiked into skin swab samples at the concentration   
1×10
4  copies/mL. The VZV whole organism was spiked into skin swab specimens at   
1×10
0 TCID50/mL.  
To evaluate the performance of the RNA assay for positive clinical samples, pooled serum samples 
that previously tested negative with this assay were aliquoted into 400μL samples and used for the 
spiking experiment. Twenty serum samples were spiked with whole organism of each of the serotypes 
of dengue virus (80 total) and 6 serum samples were run as negative specimens with each serotype of 
dengue virus (24 total). Dengue 1 and dengue 2 were spiked at 1×10
-2 dilution, the concentration of 
which was 2 logs higher than the LOD of dengue 1 and 1 log higher than the LOD of dengue 2. 
Dengue 3 was spiked at 5×10
5 LD50/mL, the concentration of which was 1.5 logs higher than the LOD 
of dengue 3. Dengue 4 was spiked at 1×10
4 LD50/mL, the concentration of which was 2 logs higher 
than the LOD of dengue 4. All of these spiked specimens were tested blindly. 
5. Conclusion 
The presented data demonstrates that the multiplex BioT DNA assay and BioT RNA assay are 
highly sensitive, specific and reproducible in testing genomic DNA, recombinant plasmid positive 
control, RNA transcription, whole organism and spiked clinical specimens utilizing a standard 
thermocycler. The assays are also rapid (~5 hrs ), utilizes relatively inexpensive reagents (~$50 for 1 
sample which was tested for all target analytes, ~$10/analyte) and requires little technician time per 
sample (~3 hrs). Compared to other currently available assays for laboratory diagnosis of bioterrorism 
agents, the BioT assays represents useful new tools for clinicians and public health officials who need Viruses 2009, 1                              
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to detect these important pathogens in people either from natural infection or man-made exposure (bio-
terrorism).  
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